Show Summary Details
Page of

Index 

Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

Subscriber: null; date: 31 October 2020

abatacept [link]
ACE (angiotensin-converting enzyme), polymorphisms [link]
acne [link]
acute hypersensitivity interstitial nephritis [link]
acute inflammatory syndrome [link]
acute kidney injury (AKI) [link]
IgAN [link]
infection-related GN [link]
intravenous immunoglobulins [link]
acute post-infectious glomerulonephritis [link]; see also post-streptococcal glomerulonephritis
adalimumab [link], [link]
adrenal insufficiency [link]
adrenocorticotropic hormone (ACTH)
clinical pharmacology [link]
clinical use [link]
FSGS [link]
GCs [link]
IgAN [link]
MCD [link]
mechanisms of action [link]
toxic effects [link]
alemtuzumab [link]
RLV [link]
alkylating agents [link]
C3G [link]
chlorambucil [link]
cyclophosphamide [link]
FSGS [link]b, [link]
nephrotic patients [link]
allergic reactions
ATCH [link]
intravenous immunoglobulins [link]
allograft rejection [link]
allopurinol [link], [link]
alopecia [link]
Alport syndrome [link], [link], [link][link], [link]
alternate-day therapy, glucocorticoids [link]
anaphylactic reactions, CTLA-4 fused proteins [link]
anasarca [link]
ANCA (anti-neutrophil cytoplasmic antibodies)
IgAN [link]
infection-related GN [link]
ANCA-associated vasculitis (ANCA-SVV) [link][link], [link], [link][link], [link], [link][link], [link][link]
azathioprine [link]
cyclophosphamide [link]
co-trimoxazole [link]
drug-associated forms [link][link]b
methotrexate vs. leflunomide [link]
mycophenolate salts [link]
overview [link]
prognostic factors [link][link]t
relapse factors [link]b
relapses [link], [link], [link]
rituximab [link]
TNF inhibition [link]
treatments [link]
ANCA negative, anti-GBM negative crescentic GN [link], [link]
ANCA negative, anti-GBM positive RLV [link]
ANCA positive, anti-GBM positive disease [link]
angiotensin-converting enzyme (ACE), polymorphisms [link]
angiotensin-converting enzyme inhibitors (ACEi)
hypertension [link]
progressive renal failure [link][link]
proteinuria [link][link]
PSGN [link]
angiotensin II receptor blockers (ARB)
hypertension [link]
progressive renal failure [link][link]
proteinuria [link][link]
antibiotics [link], [link]
anti-CD40 antibodies [link][link]
anticoagulants [link][link]
C3G [link]
factors for use [link]
IgAN [link]
anti-GBM disease [link], [link]
transplantation [link]
anti-microbials [link], [link]
anti-neutrophil cytoplasmic antibodies see ANCA
anti-PLA2R antibodies
transplantation [link]
anti-platelet agents [link]
anti-thrombotic agents
C3G [link]
IgAN [link]
anti-thymocyte globulin therapy (ATG) [link]
anti-TNFα‎ antibodies [link], [link]
auto-immune disease [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
immunogenicity [link]
infections [link]
malignancy [link]
mechanisms of action [link]
neurologic complications [link]
pregnancy [link]
toxic effects [link]
apheresis
anti-GBM disease [link]
C3G [link]
IgAN [link]
induction therapy for RLV [link]
arterial hypertension see hypertension
arteriosclerotic diseases [link][link]
aseptic necrosis [link]
ATG (anti-thymocyte globulin) therapy [link]
atypical post-infectious acute glomerulonephritis [link][link], [link][link]
auto-immune disease [link]
azathioprine
ANCA-SVV [link]
bone marrow inhibition [link]
C3G [link]
clinical use in glomerular diseases [link]
dermatological effects [link]
gastric intolerance [link]
infections [link]
interstitial nephritis [link]
liver toxicity [link]
MCD [link]
mechanisms of action [link]
metabolism [link][link]f
neoplasia [link]
pancreatitis [link]
pregnancy [link]
thiopurine metabolism [link]
toxic effects [link]


bacterial infections see infections
Bateman’s purpura [link]
belatacept [link]
bias, epidemiological data [link]
bladder toxicity, cyclophosphamide [link]
bone complications, GCs [link]
bone marrow toxicity
azathioprine [link]
chlorambucil [link]
cyclophosphamide [link]
imatinib [link]
leflunomide [link]
mTOR inhibitors [link]
mycophenolate salts [link]
bortezomib [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
haematologic events [link]
infections [link]
mechanisms of action [link]
muscular complications [link]
neurologic complications [link]
pregnancy [link]
systemic toxicity [link]
toxic effects [link]
Bowman’s space [link][link], [link]
bredinin see mizoribine
bronchiolitis obliterans [link]
bumetanide [link][link]


C1q nephropathy [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
C3 glomerulonephritis (C3GN) [link][link]; see also complement-mediated MPGN
vs. dense deposit disease [link][link]
treatment [link]
C3 glomerulopathy (C3G); see also complement-mediated MPGN
cluster analysis [link][link]t
incidence rates [link]
prognostic factors [link]t
C4 glomerulopathy [link]
clinical presentation [link]
natural history and treatments [link]
pathogenesis [link]
pathology [link]
calcineurin inhibitors (CNI)
blood level effects [link]t
C3G [link]
cyclosporine [link]
FSGS [link]t, [link]
nephrotic patients [link]
side effects [link]t
tacrolimus [link]
calcitriol [link]
cancers see malignancies
cardiac toxicity
cyclophosphamide [link]
imatinib [link]
cardiotrophin-like cytokine factor-1 (CLCF-1) [link]
cardiovascular disease
GCs [link]
rituximab [link]
cellular proliferation [link], [link][link]
cellular variant focal and segmental glomerulosclerosis [link]
chlorambucil [link]
bone marrow toxicity [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
gastrointestinal symptoms [link]
gonadal toxicity [link]
malignancy [link]
MCD [link]
mechanisms of action [link]
neurologic complications [link]
ocular complications [link]
pregnancy [link]
toxic effects [link]
chronicity index [link]
chronic kidney disease (CKD)
C3G [link]
IgAN [link][link]
infection-related GN [link], [link]
proteinuria [link], [link][link]
PSGN [link]
statins [link][link]
coagulation abnormalities, nephrotic syndrome [link]b
Cockcroft–Gault equation [link][link]
collagenofibrotic glomerulopathy [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link][link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
collapsing variant focal and segmental glomerulosclerosis [link]
complement inhibition [link]
RLV [link]
complement-mediated MPGN (C3 glomerulopathy; C3G) [link], [link]
age/sex [link]
alkylating agents [link]
anticoagulants and antithrombotics [link]
azathioprine [link]
clinical presentation [link]
CNI [link]
cyclosporine [link]
definition [link]
eculizumab [link]
epidemiology [link]
GCs [link]
hypertension [link]
impaired renal function [link]
laboratory values [link]
monoclonal antibodies [link]
monoclonal gammopathy [link]
morphology [link]
mycophenolate salts [link]
natural history [link]
pathology and pathogenesis [link]
plasma exchange [link]
practical recommendations [link]
prognostic factors [link]
proteinuria [link]
purine synthesis inhibitors [link]
rituximab [link]
tacrolimus [link]
treatments [link]
connexin 43 [link]
corticosteroids see glucocorticoids
corticosterone [link]
cortisol [link], [link]
cortisone [link]
co-trimoxazole [link]
crescentic glomerulonephritis [link]
classification [link]t
prognostic factors [link]t
crescents [link]
CsA see cyclosporine
CTLA-4 fused proteins [link]
anaphylactic reactions [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
infections [link]
infusion reactions [link]
malignancy [link]
mechanisms of action [link]
toxic effects [link]
CTLAIg fusion protein [link][link]
Cushing syndrome [link], [link]
cutaneous complications, levamisole [link]
cyclical therapy, membranous nephropathy [link], [link][link]t, [link][link]
cyclophosphamide [link]
bladder toxicity [link]
bone marrow toxicity [link]
cardiac toxicity [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
dermatological effects [link]
gastrointestinal symptoms [link]
gonadal toxicity [link]
hyponatraemia [link]
IgAN [link]
induction therapy for RLV [link]
infections [link]
liver toxicity [link]
lung toxicity [link]
MCD [link]
mechanisms of action [link]
metabolism [link]f
neoplasia [link]
pregnancy [link]
toxic effects [link]
cyclosporine (CsA) [link], [link]t
arterial hypertension [link]
C3G [link]
clinical pharmacokinetics [link]
clinical use in glomerular diseases [link]
dermatological effects [link]
electrolyte abnormalities [link]
FSGS [link]
gastrointestinal and hepatic complications [link]
gingival hyperplasia [link]
glucose intolerance [link]
hyperlipidaemia [link]
hyperuricaemia [link]
immunoglobulin M nephropathy [link]
MCD [link]
mechanisms of action [link]
musculoskeletal pain [link]
neoplasia [link]
nephrotoxicity [link]
neurologic complications [link]
pregnancy [link]
toxic effects [link]
cytokine release syndrome [link]


danazol [link]
deep venous thrombosis (DVT) [link]
deflazacort [link]
degenerative diseases [link][link]
de novo focal and segmental glomerulosclerosis, transplantation [link]
dense deposit disease (DDD) [link][link]; see also complement-mediated MPGN
vs. C3GN [link][link]
long-term prognosis [link][link]
therapy [link][link]
deoxyspergualin (DSG) [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
gastrointestinal symptoms [link]
infections [link]
leukopenia [link]
mechanisms of action [link]
pregnancy [link]
RLV [link]
toxic effects [link]
dermatological effects
azathioprine [link]
cyclophosphamide [link]
cyclosporine [link]
GCs [link]
diabetes mellitus [link], [link]
diabetic nephropathy without diabetes (DNND) see idiopathic nodular glomerulosclerosis
dietary approaches [link]
diet modification, renal disease (MDRD) [link]b
dual antibody disease [link], [link]
DVT (deep venous thrombosis) [link]


eculizumab [link]
C3G [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
IgAN [link][link]
infections [link]
infusion reactions [link]
mechanisms of action [link]
meningococcal meningitis [link]
pregnancy [link]
toxic effects [link]
EDD (electron dense deposits) [link]
elderly patients, membranous nephropathy [link]
electrolyte abnormalities [link], [link]
electron dense deposits (EDD) [link]
endostreptosins [link][link]
end-stage renal disease (ESRD) [link]
anti-GBM disease [link]
fibrillary glomerulonephritis [link][link]
FSGS [link]
glomerular disease [link]
idiopathic nodular glomerulosclerosis [link]
IgAN [link][link]
infection-related GN [link][link]
lipoprotein glomerulopathy [link]
minimal change disease [link]
epidemiology, glomerular diseases [link]
epidermal growth factor /monocyte chemotactic peptide-1-1 ratio [link]
estimated glomerular filtration rate (eGFR)
modification of diet in renal disease [link]b
etanercept [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
infections [link]
injection site reactions [link]
malignancy [link]
mechanisms of action [link]
neurologic complications [link]
RLV [link]
toxic effects [link]
etiopathogenetic classification [link]
extracapillary glomerulonephritis [link]


Fabry’s disease [link]
fibrillary glomerulonephritis (FGN) [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
fish oils [link]
fludarabine [link][link]
focal and segmental glomerulosclerosis (FSGS) [link][link], [link][link], [link]
adrenocorticotropic hormone [link]
aetiology [link]
age [link]
alkylating agents [link]b, [link]
apheresis [link]
arterial hypertension [link]
causes [link][link]t
clinical presentation [link]
cyclosporine [link]
definition [link]
epidemiology [link]
ethnicity [link]
GCs [link]
gender [link]
genetics [link]
genetic testing [link]
glomerular crescents [link]
glomerular hypertrophy [link]
histological variants [link]
hyperlipidaemia [link]
incidence rates [link]
mesangial proliferation [link]
miscellaneous treatments [link]
mycophenolate salts [link]
natural history [link]
nephrotic patients [link], [link]
non-nephrotic patients [link]
number of glomeruli affected [link]
pathogenesis [link][link]f, [link], [link][link]
pathology [link]
practical recommendations [link]
primary vs. secondary [link]t, [link]
prognostic factors [link]
proteinuria [link]
recurrence after transplantation [link]t
refractory to treatment [link]
renal function [link]
renal insufficiency [link]
response to therapy [link]
rituximab [link]
sirolimus [link]
spontaneous remission [link]
suPAR levels [link]
tacrolimus [link]
transplantation [link]
treatments [link], [link]f
tubulointerstitial changes [link]
vitamin D binding protein [link]
foetal risk classification [link]t
fungi [link]
furosemide [link][link]
fusion proteins [link], [link]


galactose [link]
garland pattern [link]
gastric intolerance, azathioprine [link]
gastrointestinal symptoms
chlorambucil [link]
cyclophosphamide [link]
cyclosporine [link]
deoxyspergualin [link]
imatinib [link]
leflunomide [link]
mycophenolate salts [link]
tacrolimus [link]
GBM (glomerular basement membranes) [link]
gene mutations, focal and segmental glomerulosclerosis [link]t
generic focal and segmental glomerulosclerosis [link][link]
genetics [link], [link]
genomic effects, glucocorticoids [link][link]
gingival hyperplasia [link]
glomerular basement membranes (GBMs) [link]
glomerular capillaries [link]
glomerular crescents [link]
glomerular diseases
classification [link]
definition [link]
epidemiology [link]
list [link]b
glomerular filtration rate (GFR) [link]
glomerular filtration rate estimation (eGFR)
modification of diet in renal disease [link]b
glomerular filtration rate (GFR) reduction
assessment [link][link]b
clinical features, pathogenesis, pathophysiology [link]
management [link]
progressive renal failure [link]
RLV [link]
therapy [link]
glomerular hypertrophy [link][link], [link]
glomerular lesions [link][link]
MCD [link]
pathological stage 1 [link]
pathological stage 2 [link]
pathological stage 3 [link]
pathological stage 4 [link]
glomerulonephritis (GN); see also membranoproliferative glomerulonephritis
classification [link]
definition [link]
glucocorticoid receptors (GRs) [link][link]f
glucocorticoids (GCs)
anti-GBM disease [link]
anti-inflammatory and immunosuppressive effects [link]
ATCH [link]
C1q nephropathy [link]
C3G [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
genomic and nongenomic effects [link]t
genomic effects [link][link]f
IgAN [link]
induction therapy for RLV [link]
mechanisms of action [link]
PSGN [link]
toxic effects [link], [link]
glucose intolerance [link]
gluten-free diet [link][link]
gonadal toxicity
chlorambucil [link]
cyclophosphamide [link]
graft failure, transplantation [link][link]
Gram-negative infections [link]
GR (glucocorticoid receptors) [link][link]f
growth retardation [link]


haematuria [link], [link]
haemolytic-uraemic syndrome (HUS) [link]
Henoch–Schönlein purpura (HSP) [link], [link]
heparin [link], [link][link]
hepatitis [link]
hepatotoxicity [link]
Heymann nephritis [link]
histological variants, FSGS [link]
Hodgkin’s lymphoma [link][link]
HSP (Henoch–Schönlein purpura) [link], [link]
humps (subepithelial deposits) [link][link], [link][link], [link]
HUS (haemolytic-uraemic syndrome) [link]
hydroxychloroquine [link]
hygienic measures, GCs [link]
hypercholesterolaemia [link], [link]
statin therapy [link]t, [link][link], [link]b
hypercoagulability
clinical features, pathogenesis, pathophysiology [link]
GCs [link]
management [link]
prophylaxis and therapy [link]
hypercortisolism [link], [link]
hyperkalaemia [link][link]
hyperlipidaemia; see also hypercholesterolaemia
clinical features, pathogenesis, pathophysiology [link]
cyclosporine [link]
FSGS [link]
GCs [link]
mTOR inhibitors [link]
tacrolimus [link]
therapy [link], [link]
hypersensitivity reactions, rituximab [link]
hypertension
C3G [link]
clinical features, pathogenesis, pathophysiology [link]
collagenofibrotic glomerulopathy [link]
cyclosporine [link]
FSGS [link]
GCs [link]
leflunomide [link]
primary glomerular disease [link]
tacrolimus [link]
therapy [link], [link]t
treatment [link], [link][link]t
hypertrichosis [link], [link][link]
hyperuricaemia [link]
hypo-adrenalism, GCs [link]
hypo-albuminaemia [link][link]
clinical features, pathogenesis, pathophysiology [link]
therapy [link]
hypocomplementaemia [link], [link]
hyponatraemia [link]
hypoproteinuria [link], [link]


idiopathic immune complex-mediated MPGN [link], [link]
idiopathic nodular glomerulosclerosis [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
transplantation [link]
treatments [link]
IgM nephropathy see immunoglobulin M nephropathy
imatinib [link]
bone marrow toxicity [link]
cardiac toxicity [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
gastrointestinal symptoms [link]
hepatotoxicity [link]
mechanisms of action [link]
musculoskeletal pain [link]
oedema [link]
pregnancy [link]
toxic effects [link]
immune complex mediated crescentic GN [link]
ANCA negative and anti-GBM negative [link]
immune complex-mediated MPGN [link], [link]; see also idiopathic immune complex-mediated MPGN
cluster analysis [link][link]t
definition [link]
practical recommendations [link]
immune-related diseases [link]
immune response, GCs [link]
immunofluorescence studies [link][link], [link]
immunogenicity [link], [link]
immunoglobulin A deposits [link], [link]b, [link]
immunoglobulin A nephropathy (IgAN) [link][link], [link]
ACEi and ARB [link]
acute and/or rapidly progressive renal failure [link]
acute or rapidly progressive glomerulonephritis [link]
adrenocorticotropic hormone [link]
advanced CKD [link]
aetiology [link]
age [link]
AKI [link]
5-aminosalicyclic acid [link]
anti-microbials [link]
anti-platelet, anti-coagulant, antithrombotic agents [link]
atypical forms [link]
azathioprine [link]
calcitriol [link]
clinical presentation [link]
CNI [link]
complement inhibition [link]
crescentic glomerulonephritis [link]
danazol [link]
diets, restricted [link]
differential diagnosis [link]
epidemiology [link]
ethnicity [link]
exposure to volatile hydrocarbons [link]
familial disease [link]
fish oils [link]
GCs [link]
gender [link]
genetically-based polymorphisms [link]
genetic predisposition [link]
geographic site [link]
glomerular crescents [link]
haematuria [link]
haematuria with proteinuria [link], [link]
HLA antigens [link]
hydroxychloroquine [link]
hypertension [link]
immunoglobulins, high-dose [link]
immunosuppressive agents [link]
incidence rates [link]
inflammatory markers [link]
isolated haematuria [link], [link]
leflunomide [link]
low birth weight [link]
management, special circumstances [link]
Manno protocol [link], [link][link]b
microRNAs [link]
mizoribine [link]
moderately reduced renal function [link]
mycophenolate salts [link]
natural history [link]
obesity, hyperuricaemia, hypertriglyceridaemia [link]
pathogenesis [link]
pathology [link]
phenytoin sodium [link]
podocytes excretion [link]
Pozzi protocol [link][link]b
practical recommendations [link]
predictive formulas or indices [link]
pregnancy [link]
prognostic factors [link]t, [link]
proteinuria [link]
renal biopsy morphology [link]
renal function [link]
rituximab [link]
sequential cyclophosphamide–azathioprine [link]
serum IgA and complement levels [link]
serum levels, gdIgA1 and auto-antibodies [link]
sodium cromoglycate [link]
statins [link]
tonsillectomy [link]
transplantation [link]
treatments [link], [link]t, [link]t, [link]f
urinary EGF/MCP-1 ratio [link]
without glomerular crescents [link]
immunoglobulin M (IgM) nephropathy [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
immunomodulating drugs, miscellaneous [link]
deoxyspergualin [link]
imatinib [link]
levamisole [link]
immunosuppressive agents, fibrillary glomerulonephritis [link]
immunotactoid glomerulopathy (ITG) [link]
incidence rates
C3G [link]
FSGS [link]
IgAN [link]
MPGN [link]
primary glomerular disease [link][link], [link][link]
induction therapy for RLV [link]
corticosteroids [link]
cyclophosphamide [link]
mycophenolate salts [link]
plasmapheresis [link]
resistance management [link]
rituximab [link]
infantile nephrosis see minimal change disease
infection-related glomerulonephritis [link]
aetiology, non-PSGN [link]
clinical presentation, non-PSGN [link]
natural history, non-PSGN [link]
non-PSGN [link]
pathogenesis, non-PSGN [link]
pathology, non-PSGN [link]
practical recommendations [link], [link][link]t
PSGN [link]
transplantation [link]
treatments, non-PSGN [link]
infections [link], [link]
anti-TNFα‎ antibodies [link]
azathioprine [link]
bortezomib [link]
CTLA-4 fused proteins [link]
cyclophosphamide [link]
deoxyspergualin [link]
eculizumab [link]
etanercept [link]
GCs [link]
leflunomide [link]
mycophenolate salts [link]
rituximab [link]
inflammation, GCs [link]
inflammatory diseases [link][link]
infliximab [link]
RLV [link]
influenza-like syndrome, intravenous immunoglobulins [link]
infusion reactions
CTLA-4 fused proteins [link]
eculizumab [link]
injection site reactions, etanercept [link]
interleukin 2 (IL2)
FSGS [link]
MCD [link]
interstitial lung disease, rituximab [link]
interstitial nephritis, azathioprine [link]
interstitial pneumonia, mTOR inhibitors [link]
intraglomerular inflammation [link]
intravenous immunoglobulins (IVIg) [link]
AKI [link]
allergic reactions [link]
clinical use in glomerular diseases [link]
haemolysis [link]
influenza-like syndrome [link]
mechanisms of action [link]
pregnancy [link]
thrombosis [link]
toxic effects [link]
isolated haematuria [link]
ITG (immunotactoid glomerulopathy) [link]


joint pain see musculoskeletal pain


kidney see renal entries
Kidney Disease: Improving Global Outcomes (KDIGO) guidelines
MCD [link]
Krüppel-like transcription factors (KLF)
FSGS [link][link]


lanthanic deposits, IgA [link], [link][link]
LDL-apheresis (LDL-A) [link][link]
lectin pathway [link]
leflunomide [link]
ANCA-SVV [link]
bone marrow toxicity [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
gastrointestinal symptoms [link]
hepatotoxicity [link]
hypertension [link]
IgAN [link]
infections [link]
mechanisms of action [link]
pregnancy [link]
toxicity [link]
leukopenia [link]
levamisole [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
cutaneous complications [link]
MCD [link]
mechanisms of action [link]
pregnancy [link]
toxic effects [link]
vasculitis [link]
lipid disturbances [link]b, [link]b; see also hyperlipidaemia
lipoid nephrosis [link][link]
lipoprotein glomerulopathy (LPG) [link]
aetiology [link]
clinical presentation [link]
diagnosis [link]
epidemiology [link]
main features [link][link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
lipoproteins, metabolism changes, NS [link][link], [link]b
liver toxicity
azathioprine [link]
cyclophosphamide [link]
locally acting GCs [link]
loop-acting diuretics
hypertension [link][link]
mild oedema [link][link]
moderate oedema [link][link]
PSGN [link]
severe oedema [link]
lung toxicity
cyclophosphamide [link]
mycophenolate salts [link]


magnesium deficiency, cyclosporine [link], [link][link]
malignancies
anti-TNFα‎ antibodies [link]
chlorambucil [link]
CTLA-4 fused proteins [link]
etanercept [link]
MN [link][link], [link]t, [link][link]
rituximab [link]
tacrolimus [link]
mammalian target of rapamycin (mTOR) inhibitors [link]
bone marrow toxicity [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
haemolytic-uraemic syndrome [link]
hyperlipidaemia [link]
interstitial pneumonia [link]
joint pain [link]
mechanisms of action [link]
mouth ulcers [link]
neoplasia [link]
oedema [link]
proteinuria [link]
retarded wound healing [link]
toxic effects [link]
MDRD (diet modification, renal disease) [link]b
melanocyte-stimulating hormones (MSH) see adrenocorticotropic hormone
membranoproliferative glomerulonephritis (MPGN) [link][link], [link][link]; see also complement-mediated MPGN; immune complex-mediated MPGN
immunopathogenetic classification [link][link]f
incidence rates [link]
transplantation [link]
membranoproliferative pattern of injury [link], [link]b, [link], [link][link]
membranous nephropathy (MN) [link][link], [link][link], [link]
adrenocorticotropic hormone [link]
aetiology [link]
age [link]
alkylating agents [link]
anti-PLA2R antibodies [link]
azathioprine [link]
causes [link][link]t
clinical presentation [link]
CNI [link]
cyclical therapy [link], [link][link]t
cyclosporine [link][link]t, [link]
declining renal function [link]
definition [link]
elderly patients [link]
epidemiology [link]
ethnicity [link]
FSGS [link][link]
GCs [link]
gender [link]
glomerular lesions [link]
HLA alleles [link]
incidence rates [link][link]
intravenous immunoglobulins [link]
mizoribine [link]
mycophenolate salts [link]
natural history [link]
nephrotic patients [link], [link]
non-nephrotic patients [link]
pathogenesis [link], [link]f
pathology [link]
practical recommendations [link]
primary vs. secondary [link][link]t, [link]
prognostic factors [link]t, [link]
proteinuria [link]
purine synthesis inhibitors [link]
remission [link]
renal complications [link]
renal insufficiency [link], [link]
rituximab [link], [link]t
specific treatment [link]
tacrolimus [link][link]t, [link]
TNF [link]
transplantation [link]
treatment [link]
treatment objectives [link]
tubulointerstitial lesions [link]
meningococcal meningitis, eculizumab [link]
mercaptopurine see azathioprine
mesangial hypercellularity [link][link]
mesangial IgM deposition [link][link]
mesangial pattern [link]
mesangial proliferative glomerulonephritis (MesPGN) [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
mesangiocapillary glomerulonephritis see membranoproliferative glomerulonephritis
MESNA (sodium 2-mercaptoethanesulphonate) [link]
metabolic syndrome
GCs [link]
IgAN [link][link]
methotrexate
ANCA-SVV [link]
RLV [link]
methylprednisolone (MP)
GCs [link]
glomerular diseases [link]
pulse therapy [link], [link], [link][link]
metolazone, moderate oedema [link][link]
microRNAs [link]
mild oedema [link], [link]b
minimal change disease (MCD) [link][link], [link]
ACTH [link]
aetiology [link]
age [link]
azathioprine [link]
chlorambucil [link]
clinical presentation [link]
cyclophosphamide [link]
cyclosporine [link]
definitions [link], [link][link]t
epidemiology [link]
frequent relapses and steroid dependency [link]
FSGS [link]
genetics [link]
glomerular lesions [link]
infrequent relapses [link]
initial treatment [link]
interleukin 2 [link]
levamisole [link]
low birth weight [link]
mechanistic interpretation [link]f
mizoribine [link]
mycophenolate salts [link]
natural history [link]
pathogenesis [link]
pathology [link]
possible causes [link][link]t
practical recommendations [link]
presentation [link]
prognostic factors [link]t, [link]
proteinuria [link]
race-ethnicity [link]
relapses [link]
remission duration [link]
rituximab [link]
spontaneous remission [link]
steroid-resistant patients [link], [link]
tacrolimus [link]
therapeutic approaches [link]f
transplantation [link]
treatment [link], [link]
mizoribine (MZB) [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
IgAN [link]
MCD [link]
mechanisms of action [link]
toxicity [link]
MMF (mycophenolate mofetil) see mycophenolate salts
moderate oedema [link]b, [link]
monoclonal antibodies
alemtuzumab [link]
anti-TNFα‎ antibodies [link]
C3G [link]
eculizumab [link]
ofatumumab [link]
rituximab [link]
monoclonal gammopathy [link]
mortality hazard ratio [link]
mouth ulcers [link]
MSH (melanocyte-stimulating hormones) see adrenocorticotropic hormone
muscular complications
bortezomib [link]
GCs [link]
musculoskeletal pain [link]
cyclosporine [link]
imatinib [link]
mycophenolate mofetil (MMF) see mycophenolate salts
mycophenolate salts [link]
acute inflammatory syndrome [link]
ANCA-SVV [link]
bone marrow toxicity [link]
C3G [link]
clinical use in glomerular diseases [link]
FSGS [link]
gastrointestinal symptoms [link]
IgAN [link]
induction therapy for RLV [link]
infections [link]
lung toxicity [link]
MCD [link]
mechanisms of action [link]
MPA metabolism [link]f, [link]
neoplasia [link]
nephrotic patients [link]
pregnancy [link]
progressive multifocal leukoencephalopathy [link]
toxic effects [link]
mycophenolate sodium (MS) see mycophenolate salts
myopathy, steroid-induced [link][link]
MZB see mizoribine


nail-patella syndrome [link]
neoplasia; see also malignancies
azathioprine [link]
cyclophosphamide [link]
cyclosporine [link]
mTOR inhibitors [link]
mycophenolate salts [link]
nephritic syndrome [link][link]
nephritis-associated plasmin receptor [link][link]
nephritis strain-associated protein [link][link]
nephrosis [link][link]
nephrotic proteinuria [link][link]
nephrotic syndrome (NS)
alkylating agents [link]
children [link][link]
CNI [link]
coagulation abnormalities [link]b
definition [link][link]
FSGS [link]
laboratory diagnoses [link][link]b
lipid disturbances [link]b, [link]b
MCD [link]
mycophenolate salts [link]
oedema [link][link]
prolonged steroid treatment [link]
rituximab [link]
treatment [link], [link], [link], [link]
nephrotoxicity
cyclosporine [link]
tacrolimus [link]
neurologic complications
anti-TNFα‎ antibodies [link]
bortezomib [link]
chlorambucil [link]
cyclosporine [link]
etanercept [link]
tacrolimus [link]
neuropsychiatric complications, GCs [link]
neutral endopeptidase [link][link]
new oral anticoagulants [link][link]
non-genomic effects, GCs [link]
non-steroidal anti-inflammatory drugs (NSAIDs) [link][link]
proteinuria [link]
nucleotide synthesis inhibitors
azathioprine [link]
leflunomide [link]
mizoribine [link]
mycophenolate salts [link]


obesity, GCs [link]
ocular complications
chlorambucil [link]
GCs [link]
oedema
clinical features, pathogenesis, pathophysiology [link]
imatinib [link]
management [link], [link]b
mild [link]
mTOR inhibitors [link]
pathogenesis [link]t
pathophysiology [link]f
severe/refractory [link]
therapy [link]
thrombo-embolic complications [link][link]
ofatumumab [link]
clinical use in glomerular diseases [link]
mechanisms of action [link]
toxic effects [link]
oligo-antigenic diet [link][link]
omega-3 polyunsaturated fatty acids [link], [link]
osteoporosis, glucocorticoids [link]
OXFORD-MEST classification system [link], [link][link], [link][link], [link], [link]


pancreatitis, azathioprine [link]
pathological classification, glomerular diseases [link][link]
pauci-immune necrotizing and crescentic GN vasculitis
ANCA negative and anti-GBM negative [link], [link]
transplantation [link]
peptic ulcers, glucocorticoids [link]
perihilar variant focal and segmental glomerulosclerosis [link]
persistent glomerular haematuria [link]
phenytoin sodium [link]
pigmentation, ACTH [link]
pirfenidone [link]
plasma exchange (PLEX) see apheresis
plasma infusion, complement-mediated MPGN [link]
plasmapheresis see apheresis
PML (progressive multifocal leukoencephalopathy) [link]
podocyte factors, focal and segmental glomerulosclerosis [link][link]
podocytopathies [link]
FSGS [link][link]
post-streptococcal glomerulonephritis (PSGN) [link]
aetiology [link]
angiotensin-converting enzyme inhibitors [link]
antibiotics [link]
clinical presentation [link], [link][link]t
epidemiology [link]
GCs [link]
hypertension [link]
loop diuretics [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
treatments [link]
Pozzi protocol, IgAN [link][link], [link][link]b, [link], [link][link], [link]
pre-absorbing antigens [link][link]
prednisolone [link]
glomerular diseases [link]
prednisone [link]
glomerular diseases [link]
pregnancy
anti-TNFα‎ antibodies [link]
azathioprine [link]
bortezomib [link]
chlorambucil [link]
cyclophosphamide [link]
cyclosporine [link]
deoxyspergualin [link]
eculizumab [link]
GCs [link]
IgAN [link]
imatinib [link]
intravenous immunoglobulins [link]
leflunomide [link]
levamisole [link]
mTOR inhibitors [link]
mycophenolate salts [link]
rituximab [link]
tacrolimus [link]
primary glomerular disease, classification [link]
progressive multifocal leukoencephalopathy (PML) [link]
progressive renal failure
clinical features, pathogenesis, pathophysiology [link]
evaluation [link][link]b
therapy [link]
proteasome inhibitors [link]
proteinuria [link]
C3G [link]
clinical features, pathogenesis, pathophysiology [link]
collagenofibrotic glomerulopathy [link]
FSGS [link]
MCD [link]
mTOR inhibitors [link]
renal disease progression [link]t
RLV [link]
therapy [link]
protozoa [link]
pseudotumour cerebri [link]
pulmonary embolism [link], [link][link]
purine synthesis inhibitors
C3G [link]


recurrent IgAN, transplantation [link], [link][link]
refractory oedema [link]b
remission, membranous nephropathy [link]
renal biopsy [link][link]
collagenofibrotic glomerulopathy [link]
immune complex-mediated MPGN [link]
infection-related GN [link]
thin basement membrane nephropathy [link][link]
renal complications, membranous nephropathy [link]
renal failure
C1q nephropathy [link]
collagenofibrotic glomerulopathy [link][link]
FSGS [link]
lipoprotein glomerulopathy [link][link]
mesangial proliferative glomerulonephritis [link][link]
minimal change disease [link]
renal function, RLV [link][link], [link]
renal insufficiency
FSGS [link]
renal-limited vasculitis (RLV) [link], [link]
aetiology [link]
age and gender [link]
ANCA negative and anti-GBM negative [link]
ANCA-SVV [link]
clinical presentation [link]
definition [link]
epidemiology [link]
induction therapy [link]
initial treatment [link]t
malignancies [link]
morphology [link]
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
prognostic factors [link]
proteinuria [link]
renal function [link]
serology [link]
transplantation [link]
treatment timeliness [link]
renal vasculitis [link], [link][link], [link]
renal vein thrombosis (RVT) [link]
renin-angiotensin system (RAS) inhibition
C3G [link]
renoprotective agents [link]
rituximab (RTX) [link]
ANCA-SVV [link]
bronchiolitis obliterans [link]
C1q nephropathy [link]
C3G [link]
cardiovascular complications [link]
clinical pharmacology [link]
clinical use in glomerular diseases [link]
cytokine release syndrome [link]
fibrillary glomerulonephritis [link]
haematologic events [link]
hypersensitivity reactions [link]
IgAN [link]
immunogenicity [link]
induction therapy for RLV [link]
infections [link]
interstitial lung disease [link]
malignancy [link]
MCD [link]
mechanisms of action [link][link]f, [link]
nephrotic patients [link]
pregnancy [link]
toxic effects [link]


saquinavir [link]
sclerosis index [link]
secondary focal and segmental glomerulosclerosis, causes [link][link]t
secondary glomerular disease, classification [link]
selective GR agonists [link]
severe oedema [link]b
severe/refractory oedema [link]
single morning-dose therapy [link]
smoking
idiopathic nodular glomerulosclerosis [link]
risk factor, kidney disease [link]
sodium 2-mercaptoethanesulphonate (MESNA) [link]
sodium chloride renal retention [link], [link][link]
sodium cromoglycate [link]
soluble urokinase-type plasminogen activator receptor (suPAR) [link][link], [link]
SPRINT trial, non-diabetic hypertension [link][link]
staphylococcal infections [link]
IgAN [link][link]
infection-related GN [link], [link][link]t
starry sky pattern [link]
statins
hypercholesterolaemia, NS [link][link], [link]b
IgAN [link]
steroids; see also glucocorticoids
C3G [link]
dependency [link]
induced myopathy [link]
prolonged treatment [link]
resistance [link], [link], [link][link]
streptococcal pyrogenic exotoxin B [link][link]
streptococcus-related disease see post-streptococcal glomerulonephritis
subepithelial deposits [link][link], [link][link], [link]
suPAR (soluble urokinase-type plasminogen activator receptor) [link][link]
symptomatic therapy [link], [link]b
fluid and electrolyte and acid-base disorders [link]
general management principles [link]
GFR reduction and progressive renal failure [link]
hypercoagulability [link]
hyperlipidaemia [link]
hypertension [link]
mild oedema [link]
moderate oedema [link]
oedema [link]
proteinuria and hypo-albuminaemia [link]
severe/refractory oedema [link]
targets [link]b
syndromes, glomerular disease [link][link]
synechia [link][link]
systemic lupus erythematosus (SLE) [link], [link][link]
MesPGN [link]
systemic toxicity, bortezomib [link]


tacrolimus (TAC) [link]
C3G [link]
clinical use in glomerular diseases [link]
diabetes mellitus [link]
electrolyte disturbances [link]
FSGS [link]
gastrointestinal symptoms [link]
hyperlipidaemia [link]
hypertension [link]
malignancy [link]
MCD [link]
mechanisms of action [link]
metabolism [link]
nephrotoxicity [link]
neurologic complications [link]
pregnancy [link]
toxic effects [link]
tetracycline [link]
thiazide diuretics
hypertension [link][link]
moderate oedema [link]
severe oedema [link][link]
thin basement membrane nephropathy (TBMN) [link]
aetiology [link]
clinical presentation [link]
epidemiology [link]
main features [link]t
natural history [link]
pathogenesis [link]
pathology [link]
practical recommendations [link]
transplantation [link]
treatments [link]
thiopurine metabolism [link], [link][link]
thromboembolic events [link][link]
oedema [link][link]
prophylactic treatments [link][link]
thrombosis; see also deep vein thrombosis; renal vein thrombosis
intravenous immunoglobulins [link]
tip variant focal and segmental glomerulosclerosis [link]
tolvaptan [link][link]
tonsillectomy, IgAN [link], [link][link]
transplantation
anti-GBM disease [link]
de novo FSGS [link]
de novo MN [link]
FSGS [link]t, [link]
IgAN [link]
infection-related GN [link]
MCD [link]
MPGN recurrence [link]
pauci-immune necrotizing and crescentic GN vasculitis [link]
recurrent FSGS [link]
recurrent MN [link]
tubular proteinuria [link]
tubulointerstitial changes, focal and segmental glomerulosclerosis [link]
tubulointerstitial lesions, membranous nephropathy [link]
tumour necrosis factor (TNF)
ANCA-SVV [link]
FSGS [link][link]


urinary EGF/MCP-1 ratio [link]


vascular endothelial growth factor (VEGF) [link][link], [link]
viruses [link]
vitamin D binding protein (VDBP) [link]
vitamin supplements [link]


warfarin [link][link]
wound healing, retarded [link]


yes-associated protein (YAP) [link][link]